Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.

Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-7-like cytokine expressed by epithelial cells during allergic inflammation, and activating dendritic cells (DC). Its expression and functional role in cancer remain controversial. We conducted retrospective (n = 89), and prospective studies including patients with untreated primary head and neck squamous cell carcinoma (HNSCC). We found that TSLP was overexpressed by HNSCC tumor cells, and associated with a highly differentiated status. However, no significant difference in overall and recurrence-free survival was found between patients bearing a tumor with high and low TSLP levels, respectively. Surprisingly, there was no significant association between the levels of TSLP expression, and the number of tumor-infiltrating mature DCLAMP(+) DC. In order to explain the apparent lack of TSLP-induced DC activation, we performed phenotypic and functional experiments on freshly resected tumors. Tumor-infiltrating immune cells, including DC, did not express the TSLP receptor heterodimer (TSLPR chain, IL-7Ralpha chain). Furthermore, freshly sorted blood CD11c(+) DC from healthy donors cultured with tumor-conditioned supernatant exhibited an activated profile, but this was not affected by an anti-TSLP blocking antibody, suggesting a DC activation pathway independent of tumor-derived TSLP. Overall, our results demonstrate that TSLP is overexpressed in HNSCC but its function is hampered by the lack of TSLPR-expressing cells in the tumor microenvironment. Such a dissociated ligand-receptor expression may impact intercellular communication in other immune activation pathways, and tumor types.

Comparison of negative pressure wound therapy and conventional dressing methods for fibula free flap donor site management in patients with head and neck cancer.

BACKGROUND: Evaluation of the efficacy of negative pressure wound therapy in fibula free flap donor site management in head and neck cancer. METHODS: We conducted a single-center retrospective study from 2007 to 2013 comparing fibula free flap donor site healing time after conventional bolster dressing or negative pressure wound therapy. RESULTS: Thirteen patients were treated by conventional dressing and 16 patients were treated by negative pressure wound therapy. The mean graft loss rate was higher in the bolster group (37%) than in the negative pressure wound therapy group (19%). The mean total healing time was significantly shorter in the negative pressure wound therapy group than in the bolster group (67 days vs 163 days; p = .02). CONCLUSION: The use of negative pressure wound therapy for fibula free flap donor site management facilitates early patient mobilization, ensures better graft acceptance, and significantly decreases the healing time.

Are the obstruction sites visualized on drug-induced sleep endoscopy reliable?

PURPOSE: Drug-induced sleep endoscopy (DISE) has been claimed to be a reliable tool, improving surgical results in obstructive sleep apnea syndrome (OSAS). One means of assessing reliability would be to ablate only a part of the sites observed on endoscopy and find only partial success versus ablating all observed sites and finding resolution of apnea. METHODS: A retrospective study included 24 OSAS patients, operated on following awake clinical examination. DISE was performed prior to surgery. Overnight sleep study was performed before and after surgery. Two groups of patients were obtained: success (postoperative apnea-hypopnea index (AHI) <10 and >50 % reduction in preoperative AHI) and failure. Obstruction sites found on DISE and those ablated or left after surgery were compared between the two groups. RESULTS: Mean AHI fell from 30.9 ± 12.4/h to 13.7 ± 14.2/h after surgery. In eight of the 14 patients in the success group, DISE showed an obstruction site not treated by surgery. In six patients out of the ten patients in the failure group, all DISE sites were treated by surgery, which nevertheless was not effective. Four patients had retrovelar concentric obstruction. CONCLUSION: DISE could in some cases explain surgical failure. However, it also seems to show additional obstruction sites which do not need to be treated. Proper knowledge of pharyngeal fluid dynamics and mastery of the DISE technique would probably help us understand better some of the DISE findings.

Long-term results of surgical treatment of vocal fold nodules.

OBJECTIVES/HYPOTHESIS: To evaluate the long-term outcome of patients with vocal fold nodules treated by surgery alone, or by a combination of surgery and voice therapy and to identify factors associated with long-term recurrent dysphonia. STUDY DESIGN: Retrospective study. METHODS: All patients who had undergone surgery for vocal fold nodules in a tertiary care hospital between 1996 and 2006 were contacted. After giving their consent, they were evaluated by videostroboscopic examination of vocal fold nodules and by a subjective questionnaire including the Voice Handicap Index (VHI). RESULTS: Sixty-two out of 90 patients (69%) (60 women, 2 men with a mean age of 33 years) answered the questionnaire at a mean interval of 9.5 years after surgery. Recurrent dysphonia was observed in 19 patients (30%) at a mean interval of 5.2 years after surgery and new benign vocal fold lesions (nodules or Reinke's edema) were observed in 11 patients (18%). Absence of postoperative voice therapy was significantly associated with a higher recurrence rate (P = 0.02) (56% of recurrent dysphonia without voice therapy versus 22% with voice therapy). CONCLUSIONS: Postoperative voice therapy decreases the risk of recurrence. Vocal fold nodules can recur over a period of 5 years, consequently requiring follow-up for at least 5 years in clinical practice and in future prospective studies.